



MEN

# FIRST CANCER SITE URINARY BLADDER

## URINARY BLADDER POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

## VESCICA POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	<b>86278</b>		91208		91208		86278		70523		33375		12352		86278	91208
Person-years ▶	<b>417343</b>		432135		14792		64833		196924		107684		47901		417343	432135
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT URINARY BLADDER	11030	<b>1.29</b>	12228	<b>1.39</b>	1198	<b>4.22</b>	2030	<b>1.64</b>	4707	<b>1.21</b>	2874	<b>1.25</b>	1419	<b>1.28</b>	<b>5.97</b>	<b>7.88</b>
HEAD AND NECK	526	<b>1.45</b>	543	<b>1.44</b>	17	1.31	87	<b>1.54</b>	245	<b>1.43</b>	136	<b>1.45</b>	58	<b>1.40</b>	<b>0.39</b>	<b>0.39</b>
ORAL CAVITY	108	<b>1.28</b>	112	<b>1.28</b>	4	1.35	17	1.32	52	1.32	26	1.19	13	1.32	0.06	0.06
PHARYNX	92	<b>1.26</b>	96	<b>1.27</b>	4	1.54	16	1.40	47	1.35	20	1.06	9	1.09	0.04	0.05
LARYNX	326	<b>1.58</b>	335	<b>1.57</b>	9	1.22	54	<b>1.67</b>	146	<b>1.50</b>	90	<b>1.70</b>	36	<b>1.55</b>	<b>0.29</b>	<b>0.28</b>
OESOPHAGUS	113	1.17	119	1.19	6	1.80	16	1.10	49	1.09	37	<b>1.47</b>	11	0.93	0.04	0.04
STOMACH	563	0.95	580	0.94	17	0.82	70	<b>0.78</b>	254	0.93	168	1.07	71	0.96	-0.07	-0.08
COLON RECTUM	1364	1.03	1422	1.04	58	<b>1.34</b>	187	0.99	595	1.00	372	1.04	210	<b>1.19</b>	0.11	0.14
COLON	954	1.05	992	1.06	38	1.29	119	0.93	432	1.06	255	1.03	148	<b>1.20</b>	0.11	0.13
RECTUM	410	1.00	430	1.01	20	1.45	68	1.13	163	0.86	117	1.06	62	1.18	0.00	0.01
LIVER	409	1.07	425	1.08	16	1.24	56	0.99	174	0.99	122	<b>1.21</b>	57	1.18	0.07	0.07
GALLBLADDER	100	0.94	104	0.94	4	1.12	20	1.29	48	0.99	24	0.84	8	0.57	-0.02	-0.01
PANCREAS	300	<b>1.16</b>	312	<b>1.17</b>	12	1.40	46	1.23	141	<b>1.20</b>	71	1.02	42	1.22	0.10	0.10
LUNG	3074	<b>1.84</b>	3404	<b>1.97</b>	330	<b>5.77</b>	370	<b>1.48</b>	1373	<b>1.78</b>	896	<b>2.03</b>	435	<b>2.09</b>	<b>3.36</b>	<b>3.87</b>
SKIN MELANOMA	141	1.14	153	<b>1.20</b>	12	<b>3.08</b>	17	0.99	67	1.21	39	1.15	18	1.06	0.04	0.06
MESOTHELIOMA	49	1.02	53	1.07	4	2.62	4	0.59	24	1.11	13	1.00	8	1.23	0.00	0.01
KAPOSI SARCOMA	12	0.59	13	0.62	1	1.42	1	0.33	8	0.86	2	0.38	1	0.39	-0.02	-0.02
SOFT TISSUE	42	1.32	42	1.28	0	0.00	8	1.73	14	0.97	11	1.29	9	2.16	0.02	0.02
BONE	12	1.46	12	1.41	0	0.00	1	0.78	7	1.82	3	1.42	1	1.04	0.01	0.01
BREAST	26	1.29	27	1.29	1	1.49	4	1.37	15	1.63	7	1.29	0	0.00	0.01	0.01
PROSTATE	2625	<b>1.39</b>	3212	<b>1.65</b>	587	<b>9.86</b>	871	<b>3.33</b>	977	<b>1.16</b>	516	0.99	261	1.01	<b>1.77</b>	<b>2.93</b>
TESTIS	12	1.43	17	<b>1.96</b>	5	<b>16.42</b>	2	1.50	7	1.74	2	0.95	1	1.10	0.01	0.02
KIDNEY AND RENAL PELVIS	366	<b>1.29</b>	416	<b>1.41</b>	50	<b>5.37</b>	105	<b>2.57</b>	113	0.87	95	<b>1.24</b>	53	<b>1.43</b>	<b>0.19</b>	<b>0.28</b>
BLADDER AND URINARY TRACT	85	<b>0.08</b>	120	<b>0.11</b>	35	0.96	21	<b>0.13</b>	29	<b>0.06</b>	24	<b>0.08</b>	11	<b>0.08</b>	<b>-2.39</b>	<b>-2.31</b>
URINARY BLADDER	33	<b>0.03</b>	57	<b>0.05</b>	24	0.69	15	<b>0.10</b>	9	<b>0.02</b>	6	<b>0.02</b>	3	<b>0.02</b>	<b>-2.40</b>	<b>-2.34</b>
URINARY TRACT	52	1.12	63	<b>1.31</b>	11	<b>7.20</b>	6	0.90	20	0.95	18	1.43	8	1.28	0.01	0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	84	0.81	86	<b>0.80</b>	2	0.57	9	0.58	35	0.73	29	1.06	11	0.87	-0.05	-0.05
THYROID	38	1.02	39	1.01	1	0.81	1	0.18	19	1.10	8	0.80	10	<b>2.15</b>	0.00	0.00
HODGKIN LYMPHOMA	18	1.07	19	1.09	1	1.66	0	0.00	11	1.39	5	1.16	2	1.03	0.00	0.00
NON-HODGKIN LYMPHOMA	250	0.96	261	0.97	11	1.28	28	0.74	126	1.06	62	0.89	34	1.00	-0.03	-0.02
MYELOMA	134	1.06	140	1.07	6	1.42	18	0.98	60	1.04	37	1.09	19	1.14	0.02	0.02
LEUKAEMIAS	256	<b>1.16</b>	263	<b>1.15</b>	7	0.93	34	1.04	123	<b>1.22</b>	71	1.21	28	1.00	0.09	0.08
LYMPHOID LEUKAEMIAS	100	0.96	105	0.97	5	1.39	11	0.70	51	1.06	26	0.94	12	0.92	-0.01	-0.01
MYELOID LEUKAEMIAS	140	<b>1.41</b>	141	<b>1.37</b>	1	0.30	22	1.52	66	<b>1.46</b>	38	<b>1.42</b>	14	1.07	<b>0.10</b>	<b>0.09</b>
OTHER LEUKAEMIAS	16	0.97	17	1.00	1	1.68	1	0.39	6	0.78	7	1.63	2	1.01	0.00	0.00
OTHER AND ILL DEFINED SITES	464	0.92	503	0.96	39	<b>2.31</b>	69	0.94	202	0.88	130	0.96	63	0.93	-0.10	-0.05

■ Decrease/Difetto    ○ Observed cases    ■ SIR Standardized Incidence Ratio    ■ EAR Excess Absolute Risk  
■ Increase/Eccesso    ○ Casi osservati    ■ Rapporto standardizzato di incidenza    ■ Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE

## URINARY BLADDER

URINARY BLADDER  
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

## VESCICA

## POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	21034		71790		22506		21034		16704		8321		3225		21034	71790
Person-years ▶	102871		106495		3624		15558		47146		27456		12711		102871	106495
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT URINARY BLADDER	1531	1.22	1686	1.30	155	3.59	217	1.18	670	1.19	421	1.22	223	1.32	2.65	3.61
HEAD AND NECK	26	1.62	26	1.56	0	0.00	4	1.70	15	2.08	5	1.14	2	0.94	0.10	0.09
ORAL CAVITY	8	0.89	8	0.86	0	0.00	1	0.77	4	1.00	2	0.80	1	0.80	-0.01	-0.01
PHARYNX	8	2.47	8	2.39	0	0.00	1	2.05	5	3.37	1	1.16	1	2.50	0.05	0.04
LARYNX	10	2.63	10	2.54	0	0.00	2	3.53	6	3.47	2	1.96	0	0.00	0.06	0.06
OESOPHAGUS	13	1.91	13	1.85	0	0.00	1	1.01	7	2.32	2	1.07	3	3.22	0.06	0.06
STOMACH	76	0.89	77	0.87	1	0.32	11	0.86	37	0.97	20	0.87	8	0.72	-0.09	-0.11
COLON RECTUM	201	0.95	213	0.97	12	1.65	32	1.04	86	0.91	51	0.87	32	1.10	-0.11	-0.06
COLON	153	1.00	164	1.03	11	2.11	23	1.05	72	1.06	39	0.92	19	0.90	0.00	0.05
RECTUM	48	0.82	49	0.81	1	0.49	9	1.04	14	0.53	12	0.75	13	1.67	-0.10	-0.11
LIVER	42	1.11	44	1.13	2	1.54	2	0.37	20	1.19	13	1.25	7	1.36	0.04	0.05
GALLBLADDER	26	0.85	27	0.85	1	0.92	3	0.66	13	0.96	6	0.72	4	0.98	-0.04	-0.04
PANCREAS	83	1.45	85	1.44	2	1.04	12	1.49	35	1.40	17	1.06	19	2.31	0.25	0.24
LUNG	242	2.89	279	3.23	37	13.44	29	2.47	107	2.91	69	2.97	37	3.14	1.54	1.81
SKIN MELANOMA	25	1.16	27	1.21	2	2.78	0	0.00	11	1.14	11	1.85	3	1.03	0.03	0.04
MESOTHELIOMA	4	1.17	4	1.14	0	0.00	0	0.00	1	0.67	2	2.10	1	2.06	0.01	0.00
KAPOSI SARCOMA	3	1.54	3	1.48	0	0.00	1	3.50	0	0.00	1	1.86	1	3.71	0.01	0.01
SOFT TISSUE	11	2.09	14	2.57	3	16.90	2	2.64	7	2.99	0	0.00	2	2.78	0.06	0.08
BONE	3	2.10	3	2.03	0	0.00	1	4.60	1	1.55	1	2.58	0	0.00	0.02	0.01
BREAST	347	1.15	372	1.19	25	2.42	41	0.93	149	1.09	103	1.26	54	1.39	0.45	0.57
CERVIX UTERI	23	1.52	40	2.55	17	30.21	7	2.92	10	1.41	5	1.27	1	0.58	0.08	0.23
CORPUS UTERI	53	0.97	80	1.42	27	14.28	11	1.35	21	0.84	16	1.10	5	0.74	-0.01	0.22
OVARY	42	1.08	43	1.07	1	0.74	5	0.87	23	1.31	10	0.95	4	0.80	0.03	0.03
KIDNEY AND RENAL PELVIS	47	1.50	54	1.67	7	6.78	8	1.81	21	1.51	9	1.03	9	2.07	0.15	0.20
BLADDER AND URINARY TRACT	15	0.29	27	0.50	12	6.70	5	0.66	3	0.13	5	0.34	2	0.28	-0.36	-0.26
URINARY BLADDER	8	0.16	19	0.38	11	6.62	5	0.71	1	0.05	1	0.07	1	0.15	-0.39	-0.29
URINARY TRACT	7	1.83	8	2.03	1	7.80	0	0.00	2	1.20	4	3.76	1	1.81	0.03	0.04
BRAIN AND CENTRAL NERVOUS SYSTEM	19	1.03	20	1.05	1	1.61	3	1.12	7	0.85	8	1.59	1	0.41	0.01	0.01
THYROID	24	1.31	25	1.32	1	1.63	3	1.12	16	1.91	3	0.60	2	0.85	0.05	0.06
HODGKIN LYMPHOMA	5	1.81	5	1.74	0	0.00	1	2.34	2	1.56	2	2.75	0	0.00	0.02	0.02
NON-HODGKIN LYMPHOMA	53	1.10	56	1.12	3	1.84	6	0.86	17	0.79	17	1.28	13	2.01	0.05	0.06
MYELOMA	20	0.85	22	0.90	2	2.47	5	1.46	9	0.86	5	0.77	1	0.32	-0.03	-0.02
LEUKAEMIAS	31	0.91	31	0.88	0	0.00	5	1.01	12	0.79	12	1.29	2	0.44	-0.03	-0.04
LYMPHOID LEUKAEMIAS	10	0.67	10	0.64	0	0.00	3	1.34	3	0.44	3	0.74	1	0.52	-0.05	-0.05
MYELOID LEUKAEMIAS	19	1.20	19	1.16	0	0.00	2	0.88	8	1.14	8	1.83	1	0.46	0.03	0.02
OTHER LEUKAEMIAS	2	0.64	2	0.62	0	0.00	0	0.00	1	0.73	1	1.15	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	105	1.00	115	1.06	10	2.77	24	1.60	41	0.89	29	1.00	11	0.74	0.00	0.06

Decrease/Difetto  
Increase/Eccesso

Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio